Evaluation of Thalassaemia Screening Tests in the Antenatal and Non-Antenatal Populations in Singapore.

INTRODUCTION Haemoglobinopathy testing is performed for carrier screening and evaluation of microcytic anaemia. We evaluated the effectiveness of thalassaemia screening tests at our institution and suggest ways of improving the testing algorithm. MATERIALS AND METHODS A total of 10,084 non-antenatal and 11,364 antenatal samples with alkaline gel electrophoresis (AGE), capillary electrophoresis (CE), haemoglobin H (HbH) inclusion test, mean corpuscular haemoglobin (MCH) and mean corpuscular volume (MCV) were retrospectively reviewed. A subgroup of 187 samples with genetic testing was correlated with HbH inclusions and MCH/ MCV. The effect of iron deficiency on percentage hemoglobin A2 (HbA2) was studied. RESULTS HbH inclusion test showed low sensitivity of 21.43% for α-thalassaemia mutations but higher sensitivity of 78.95% for --SEA deletion. By receiver operating characteristic (ROC) analysis, MCH ≤28 pg or MCV ≤80 fl for non-antenatal samples and MCH ≤27 pg or MCV ≤81 fl for antenatal samples had >98% sensitivity for HbH inclusions. Above these thresholds, the probability that HbH inclusions would be absent was <99% (negative predictive value [NPV] >99%). MCH ≥28 pg had 100% sensitivity (95% CI 95.63%-100%) for α-thalassaemia mutations and 97.68% calculated NPV in the antenatal population. Detection of haemoglobin variants by CE correlated highly with AGE (99.89% sensitivity, 100% specificity). Severe iron deficiency reduced HbA2 in hemoglobin (P <0.001) and α-thalassaemia (P = 0.0035), but not in β-thalassaemia. CONCLUSION MCH/MCV thresholds have adequate sensitivity for α-thalassaemia in the antenatal population, and genotyping plays an important role as HbH inclusion test shows low sensitivity. CE without AGE, may be used as initial screening for haemoglobin variants. Our study provides contemporary data to guide thalassaemia screening algorithms in Singapore.

[1]  G. Guyatt,et al.  Diagnosis of iron-deficiency anemia in the elderly. , 1990, The American journal of medicine.

[2]  A. Cao,et al.  Hematological phenotype of the double heterozygous state for alpha and beta thalassemia. , 1984, Hemoglobin.

[3]  D. Higgs,et al.  Clinical and laboratory features of a-thalassemia syndromes , 2001 .

[4]  A. A. Abu Shahla,et al.  The effect of iron deficiency anaemia on the levels of haemoglobin subtypes: possible consequences for clinical diagnosis. , 2002, Clinical and laboratory haematology.

[5]  Dina N. Greene,et al.  Comparison of Sebia Capillarys Flex capillary electrophoresis with the BioRad Variant II high pressure liquid chromatography in the evaluation of hemoglobinopathies. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[6]  M. Chee,et al.  The simultaneous presence of alpha- and beta-thalassaemia alleles: a pitfall of thalassaemia screening. , 2003, Community genetics.

[7]  Joo-In Park,et al.  Comparison of Capillary Electrophoresis with Cellulose Acetate Electrophoresis for the Screening of Hemoglobinopathies , 2011, The Korean journal of laboratory medicine.

[8]  B. Bain,et al.  Significant haemoglobinopathies: guidelines for screening and diagnosis , 2010, British journal of haematology.

[9]  B. Bain Haemoglobinopathy diagnosis: algorithms, lessons and pitfalls. , 2011, Blood reviews.

[10]  S. Chong,et al.  First successful preimplantation genetic diagnosis in Singapore--avoidance of beta-thalassaemia major. , 2009, Annals of the Academy of Medicine, Singapore.

[11]  D. Mais,et al.  The range of hemoglobin A(2) in hemoglobin E heterozygotes as determined by capillary electrophoresis. , 2009, American journal of clinical pathology.

[12]  M. Scott,et al.  Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. , 1998, Clinical chemistry.

[13]  Committee Opinion No. 691: Carrier Screening for Genetic Conditions. , 2017, Obstetrics and gynecology.

[14]  G. Gibney,et al.  Is HbA2 level a reliable diagnostic measurement for β‐thalassemia trait in people with iron deficiency? , 2012, American journal of hematology.

[15]  T. Bradley,et al.  Hemoglobin Gun Hill: an unstable protein associated with chronic hemolysis. , 1968, Blood.

[16]  Quah Thuan Chong,et al.  A Molecular Epidemiologic Study of Thalassemia Using Newborns' Cord Blood in a Multiracial Asian Population in Singapore: Results and Recommendations for a Population Screening Program , 2004, Journal of pediatric hematology/oncology.

[17]  D. Higgs,et al.  Single-tube multiplex-PCR screen for common deletional determinants of α-thalassemia , 2000 .

[18]  A. Maggio,et al.  Iron deficiency does not compromise the diagnosis of high HbA2 β thalassemia trait , 2012, Haematologica.

[19]  Jones Alana K Bergstrome,et al.  Evaluation of a single-tube multiplex polymerase chain reaction screen for detection of common alpha-thalassemia genotypes in a clinical laboratory. , 2002, American journal of clinical pathology.

[20]  C. Hoppe Prenatal and newborn screening for hemoglobinopathies , 2013, International journal of laboratory hematology.

[21]  C. Liao,et al.  Detection of alpha-thalassemia in beta-thalassemia carriers and prevention of Hb Bart's hydrops fetalis through prenatal screening. , 2006, Haematologica.

[22]  J. Biggio,et al.  Committee Opinion No. 691 Summary: Carrier Screening for Genetic Conditions. , 2017, Obstetrics and gynecology.

[23]  B. Bain,et al.  Capillary zone electrophoresis for haemoglobinopathy diagnosis , 2012, Journal of Clinical Pathology.

[24]  D. Chui α‐Thalassemia: Hb H Disease and Hb Barts Hydrops Fetalis , 2005, Annals of the New York Academy of Sciences.

[25]  Y. Lau,et al.  Should we screen for globin gene mutations in blood samples with mean corpuscular volume (MCV) greater than 80 fL in areas with a high prevalence of thalassaemia? , 2001, Journal of clinical pathology.

[26]  D. Chitayat,et al.  Carrier screening for thalassemia and hemoglobinopathies in Canada. , 2008, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[27]  Bernadette Modell,et al.  Prevention of Thalassaemias and Other Haemoglobin Disorders , 2013 .

[28]  D. Sabath Molecular Diagnosis of Thalassemias and Hemoglobinopathies: An ACLPS Critical Review , 2017, American journal of clinical pathology.

[29]  L. Chan,et al.  Comparison of the HbH inclusion test and a PCR test in routine screening for alpha thalassaemia in Hong Kong. , 1996, Journal of clinical pathology.

[30]  V. Viprakasit,et al.  Problems in determining thalassemia carrier status in a program for prevention and control of severe thalassemia syndromes: a lesson from Thailand , 2013, Clinical chemistry and laboratory medicine.

[31]  A. Barrett,et al.  Thalassaemia screening and confirmation of carriers in parents. , 2017, Best practice & research. Clinical obstetrics & gynaecology.

[32]  A. García-Raso,et al.  Cut-Off Values of Hematologic Parameters to Predict the Number of Alpha Genes Deleted in Subjects with Deletional Alpha Thalassemia , 2017, International journal of molecular sciences.

[33]  T. Tongsong,et al.  Sensitivity and specificity of mean corpuscular volume testing for screening for alpha-thalassemia-1 and beta-thalassemia traits. , 2005, The journal of obstetrics and gynaecology research.

[34]  U. Baylan,et al.  Evaluating five dedicated automatic devices for haemoglobinopathy diagnostics in multi‐ethnic populations , 2009, International journal of laboratory hematology.